ANDA 205923, held by Xellia Pharms Aps. Caspofungin Acetate.
As of Nov 15, 2026, ANDA 205923 (Caspofungin Acetate), held by Xellia Pharms Aps, was first approved by FDA on Jul 2, 2018, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 2, 2018 | Original application | Approved | None posted |
| Caspofungin Acetate50MG/VIAL · powder;intravenous | Caspofungin Acetate | Discontinued |
| Caspofungin Acetate70MG/VIAL · powder;intravenous | Caspofungin Acetate | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
